A clinical pharmacokinetics network for the Midlands
For over 10 years our group of like minded scientists based within Aston University in central Birmingham, have focused on the provision of pharmacokinetics research, both pre-clinical and clinical on a national and international level. Our research focuses on developing virtual patients, with which to study the pharmacokinetics of drugs during drug discovery and development.
We also work across clinical areas, applying population pharmacokinetics to the study and causes of variability in drug concentrations among individuals, through sparse (plasma) sampling and mathematical models to explain sources of variability and approaches to dose optimisation.
We are keen to work with colleagues within the Midlands, please get in touch to discuss opportunities for collaboration.
WELCOME TO THE
WEST MIDLANDS PHARMACOKINETICS NETWORK
REPRESENTATIVE PUBLISHED WORK
QUETIAPINE DOSE OPTIMISATION DURING GESTATION: A PHARMACOKINETICS MODELLING STUDY
February 3rd 2020
Badhan RKS, Macfarlane H. Quetiapine dose optimisation during gestation: a
pharmacokinetic modelling study. J Pharm Pharmacol. 2020 Feb 3. doi:
10.1111/jphp.13236. [Epub ahead of print] PubMed PMID: 32012278.
THE OPTIMISATION OF METHADONE DOSING WHILST TREATING WITH RIFAMPICIN: A PHARMACOKINETIC MODELLING STUDY
JULY 1ST 2019
Badhan RKS, Gittins R, Al Zabit D. The optimization of methadone dosing whilst
treating with rifampicin: A pharmacokinetic modeling study. Drug Alcohol Depend.
2019 Jul 1;200:168-180. doi: 10.1016/j.drugalcdep.2019.03.013. Epub 2019 May 20.
PubMed PMID: 31122724.
THE IMPACT OF CYP2B6 POLYMORPHISMS ON THE INTERACTIONS OF EFAVIRENZ WITH LUMEFANTRINE: IMPLICATIONS FOR PAEDIATRIC ANTIMALARIAL THERAPY
Zakaria Z, Badhan RKS. The impact of CYP2B6 polymorphisms on the interactions
of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy.
Eur J Pharm Sci. 2018 Jul 1;119:90-101. doi: 10.1016/j.ejps.2018.04.012. Epub
2018 Apr 7. PubMed PMID: 29635009.
FIXED-DOSE COMBINATION ORALLY DISINTEGRATING TABLETS TO TREAT CARDIOVASCULAR DISEASE: FORMULATION, IN VITRO CHARACTERIZATION AND PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING TO ASSESS BIOAVAILABILITY.
Dennison TJ, Smith JC, Badhan RK, Mohammed AR. Fixed-dose combination orally
disintegrating tablets to treat cardiovascular disease: formulation, in vitro
characterization and physiologically based pharmacokinetic modeling to assess
bioavailability. Drug Des Devel Ther. 2017 Mar 16;11:811-826. doi:
10.2147/DDDT.S126035. eCollection 2017. PubMed PMID: 28352156; PubMed Central